Research ArticleOriginal Article

Implantable port thrombosis in cancer patients: a monocentric experience

Manel Dridi, Nesrine Mejri, Soumaya Labidi, Mehdi Afrit, Houda El Benna, Khaoula Ben Miled and Hamouda Boussen
Cancer Biology & Medicine September 2016, 13 (3) 384-388; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0057

References

  1. 1.↵
    2. Agnes L,
    3. Levine N,
    4. Butler G,
    5. Webb C,
    6. Costantini L,
    7. Chushu G, et al.
    Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006; 24: 1404–8.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    2. Barbetakis N,
    3. Asteriou C,
    4. Kleontas A,
    5. Tsilikas C.
    Totally implantable central venous access ports. Analysis of 700 cases, J Surg Oncol. 2011; 104: 654–6.
    OpenUrlPubMed
  3. 3.↵
    2. Moritz Wildgruber,
    3. Claudia Lueg,
    4. Sebastian Borgmeyer,
    5. Ilham Karimov Ulrike Braun,
    6. Marion Kiechle, et al.
    Polyurethane versus silicone catheters for central venous port devices implanted at the forearm. Eur J Cancer. 2016; 59: 113–24.
    OpenUrl
  4. 4.↵
    2. Teichgräber U,
    3. Nagel SN,
    4. Kausche S.
    Evaluation of correlations between underlying disease and port complications interventional. Rofo. 2014; 186: 496–5.
    OpenUrl
  5. 5.↵
    2. Debourdeau P,
    3. Kassab D,
    4. Zammit C,
    5. Farge-Bancel D.
    Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Pathol Biol. 2008; 56: 211–9.
    OpenUrl
  6. 6.↵
    2. Piran S,
    3. Ngo V,
    4. McDiarmid S,
    5. LeGal G,
    6. Petrcich W,
    7. Carrier M, et al.
    Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients. Thromb Res. 2014; 133: 30–3.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Vescia S,
    3. Baumgärtner AK,
    4. Jacobs VR,
    5. Kiechle-Bahat M,
    6. Rody A,
    7. Loibl S, et al.
    Management of venous port systems in oncology: a review of current evidence. Ann Oncol. 2008; 19: 9–15.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Verso M,
    3. Agnelli.
    Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003; 21: 3665–75.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Schiffer CA,
    3. Mangu PB,
    4. Wade JC,
    5. Camp-Sorrell D,
    6. Cope DG,
    7. El-Rayes BF, et al.
    Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31: 1357–70.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Boussen H,
    3. Mtaallah M,
    4. Dhiab T,
    5. Khalfallah S,
    6. Jerbi G,
    7. Hechiche M, et al.
    Evaluation of implantable sites in medical oncology in Tunisia. Prospective study of 205 cases. Ann Fr Anesth Reanim. 2001; 20: 509–13.
    OpenUrlPubMed
  11. 11.↵
    2. Kuter DJ.
    Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004; 9: 207–16.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    2. Dal Molin A,
    3. Di Massimo DS,
    4. Braggion C,
    5. Bisogni S,
    6. Rizzi E,
    7. D’Orazio C, et al.
    Totally implantable central venous access ports in patients withcystic fibrosis: a multicenter prospective cohort study. J Vasc Access. 2012; 13: 290–5.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Biffi R,
    3. De Braud F,
    4. Orsi F,
    5. Pozzi S,
    6. Arnaldi P,
    7. Goldhirsch A, et al.
    A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer. 2001; 92: 1204–12.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Surov A,
    3. Jordan K,
    4. Buerke M,
    5. Arnold D,
    6. John E,
    7. Spielmann RP, et al.
    Port catheter insufficiency: incidence and clinical-radiological correlations onkologie. Onkologie. 2008; 31: 455–61.
    OpenUrlPubMed
  15. 15.
    2. Luciani A,
    3. Clement O,
    4. Halimi P,
    5. Goudot D,
    6. Portier F,
    7. Bassot V, et al.
    Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler USa. Radiology. 2001; 220: 655–60.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    2. Hohl Moinat C,
    3. Périard D,
    4. Grueber A,
    5. Hayoz D,
    6. Magnin JL,
    7. André P, et al.
    Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients. J Oncol. 2014; 2014: 743181.
    OpenUrl
  17. 17.↵
    2. Narducci F,
    3. Jean-Laurent M,
    4. Boulanger L,
    5. El Bédoui S,
    6. Mallet Y,
    7. Houpeau JL, et al.
    Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. Eur J Surg Oncol. 2011; 37: 913–8.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. López-Briz E,
    3. Ruiz Garcia V,
    4. Cabello JB,
    5. Bort-Marti S,
    6. Carbonell Sanchis R,
    7. Burls A.
    Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults. Cochrane Database Syst Rev. 2014 Oct 8;(10): CD008462.
  19. 19.↵
    2. Goossens GA,
    3. Jérôme M,
    4. Janssens C,
    5. Peetermans WE,
    6. Fieuws S,
    7. Moons P, et al.
    Comparing normal saline versus diluted heparin to lock non-valvedtotally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Ann Oncol. 2013; 24: 1892–9.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Dal Molin A,
    3. Clerico M,
    4. Baccini M,
    5. Guerretta L,
    6. Sartorello B,
    7. Rasero L.
    Normal saline versus heparin solution to lock totally implantedvenous access devices: Results from a multicenter randomized trial. Eur J Oncol Nurs. 2015; 19: 638–43.
    OpenUrl
  21. 21.↵
    2. Debourdeau P,
    3. Desmurs-Clave H,
    4. Pavic m,
    5. Quéré I,
    6. Kriegel I,
    7. Desruennes E, et al.
    Standards, options: recommandations 2008. Prévention et traitement des thromboses veineuses sur cathéter chez les patients atteints de cancer. La Revue de médecine interne. 2008; 29: 1058–67
    OpenUrl
  22. 22.↵
    2. Franchini M,
    3. Bonfanti C,
    4. Lippi G .
    Cancer-associated thrombosis: investigating the role of new oral anticoagulants. Thromb Res. 2015; 135: 777–81.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Kyrle PA.
    Predicting recurrent venous thromboembolism in cancer: is it possible? Thromb Res. 2014; 133(S2);S17014.
    OpenUrl
  24. 24.↵
    2. Louzada ML,
    3. Majeed H,
    4. Dao V,
    5. Wells PS.
    Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis. 2011; 22: 86–91.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Ay C,
    3. Pabinger I.
    Treatment and secondary prevention of venous thrombo -embolism in cancer patients Current strategies and new therapeutic options. Hamostaseologie. 2012; 32: 139–44.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords